We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug
Read MoreHide Full Article
Key Takeaways
Denali posted a Q3 loss of $0.74 per share, wider than last year's $0.63 loss.
FDA extended tividenofusp alfa's approval decision to April 2026 after a major amendment.
DNLI advanced programs for Sanfilippo, Alzheimer, Parkinson and Pompe diseases.
Denali Therapeutics (DNLI - Free Report) reported a third-quarter 2025 loss of 74 cents per share, narrower than the Zacks Consensus Estimate of a loss of 76 cents. The company reported a loss of 63 cents in the year-ago quarter.
The loss per share widened year over year due to an increase in total operating expenses.
In the absence of a marketed product, the company only recognizes revenues from ongoing collaborations. Denali did not generate collaboration revenues in the reported quarter. The Zacks Consensus Estimate for revenues was pegged at $14 million.
Shares of DNLI have lost 29.3% year to date against the industry’s 11.5% growth.
Image Source: Zacks Investment Research
Highlights of DNLI’s Q3 Results
Research and development expenses increased 3.8% to $101.9 million. The increase was primarily due to the commencement of operations at Denali's large molecule manufacturing facility in Salt Lake City, UT.
General and administrative expenses increased 42.2% to $35.5 million due to activities related to the preparations for a potential launch of tividenofusp alfa.
As of Sept. 30, 2025, cash, cash equivalents, and marketable securities amounted to approximately $872.9 million.
DNLI’s Regulatory and Pipeline Updates
Last month, Denali suffered a setback when the FDA extended its review timeline of the biologics license application (BLA) seeking accelerated approval of tividenofusp alfa for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome.
Consequently, the target action date has been extended to April 5, 2026, from January 5, 2026.
The BLA was extended after DNLI submitted updated clinical pharmacology information in response to an information request from the FDA as part of the standard review process. DNLI stated that the response was not related to efficacy, safety or biomarkers.
The FDA classified the submission as a major amendment (MA) to the BLA, leading to the extension of the target action date. Nevertheless, the regulatory body did not ask for additional data.
Denali believes that the updated information submitted in the amendment does not affect the clinical pharmacology or benefit-risk conclusions of the BLA.
The FDA had previously granted tividenofusp alfa Breakthrough Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease designations.
Tividenofusp alfa is an investigational, next-generation enzyme replacement therapy designed to cross the blood-brain barrier (BBB) and deliver the iduronate-2-sulfatase (IDS) enzyme throughout the body and brain.
Denali is also evaluating DNL126 for the treatment of Sanfilippo syndrome type A (MPS IIIA). In September, Denali completed enrollment in the ongoing phase I/II study of DNL126 to support an accelerated approval path in Sanfilippo syndrome type A.
Denali had earlier announced data on DNL126 that demonstrated a significant reduction in cerebrospinal fluid (CSF) heparan sulfate (HS) from baseline, including normalization, and a safety profile that supports continued development. A global phase III confirmatory study is being planned.
Denali is also developing other candidates in partnership with Takeda (TAK - Free Report) and Biogen (BIIB - Free Report) .
Denali and partner Takeda have collaborated to develop DNL593, an investigational therapeutic designed to deliver progranulin across the blood-brain barrier for the treatment of granulin (GRN) mutation-associated frontotemporal dementia (FTD-GRN). A phase I/II study is ongoing.
Last month, DNLI submitted a clinical trial application for DNL628 (OTV:MAPT) to initiate clinical studies in Alzheimer’s disease, marking a significant milestone in advancing the oligonucleotide TransportVehicle (OTV) platform.
Denali and Biogen continue co-development of BIIB122.
Biogen is leading the global phase IIb LUMA study, evaluating BIIB122's impact on disease progression in early-stage PD. In May 2025, Biogen announced that the LUMA study was fully enrolled with a readout expected in 2026.
Meanwhile, Denali is conducting the phase IIa BEACON study, specifically enrolling participants with LRRK2-associated PD to assess how LRRK2 inhibition may impact this disease.
In October, Denali submitted an investigational new drug application for DNL952 (ETV:GAA) to begin clinical studies in Pompe disease.
Denali Therapeutics Inc. Price, Consensus and EPS Surprise
While DNLI continues to advance its pipeline, a delay in approval of tividenofusp alfa is disappointing, as it is the company’s lead pipeline candidate.
Nonetheless, the company’s progress with DNL126 is encouraging as well.
The company’s sound cash position is a positive and ensures its ability to fund ongoing programs.
Alkermes’ earnings per share (EPS) estimates for 2025 have increased to $1.96 from $1.82, while those for 2026 have risen from $1.70 to $1.77 in the past 30 days. The stock has gained nearly 10.2% year to date.
Alkermes’ earnings beat estimates in three of the trailing four quarters and missed the mark in one, delivering an average surprise of 4.58%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug
Key Takeaways
Denali Therapeutics (DNLI - Free Report) reported a third-quarter 2025 loss of 74 cents per share, narrower than the Zacks Consensus Estimate of a loss of 76 cents. The company reported a loss of 63 cents in the year-ago quarter.
The loss per share widened year over year due to an increase in total operating expenses.
In the absence of a marketed product, the company only recognizes revenues from ongoing collaborations. Denali did not generate collaboration revenues in the reported quarter. The Zacks Consensus Estimate for revenues was pegged at $14 million.
Shares of DNLI have lost 29.3% year to date against the industry’s 11.5% growth.
Image Source: Zacks Investment Research
Highlights of DNLI’s Q3 Results
Research and development expenses increased 3.8% to $101.9 million. The increase was primarily due to the commencement of operations at Denali's large molecule manufacturing facility in Salt Lake City, UT.
General and administrative expenses increased 42.2% to $35.5 million due to activities related to the preparations for a potential launch of tividenofusp alfa.
As of Sept. 30, 2025, cash, cash equivalents, and marketable securities amounted to approximately $872.9 million.
DNLI’s Regulatory and Pipeline Updates
Last month, Denali suffered a setback when the FDA extended its review timeline of the biologics license application (BLA) seeking accelerated approval of tividenofusp alfa for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome.
Consequently, the target action date has been extended to April 5, 2026, from January 5, 2026.
The BLA was extended after DNLI submitted updated clinical pharmacology information in response to an information request from the FDA as part of the standard review process. DNLI stated that the response was not related to efficacy, safety or biomarkers.
The FDA classified the submission as a major amendment (MA) to the BLA, leading to the extension of the target action date. Nevertheless, the regulatory body did not ask for additional data.
Denali believes that the updated information submitted in the amendment does not affect the clinical pharmacology or benefit-risk conclusions of the BLA.
The FDA had previously granted tividenofusp alfa Breakthrough Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease designations.
Tividenofusp alfa is an investigational, next-generation enzyme replacement therapy designed to cross the blood-brain barrier (BBB) and deliver the iduronate-2-sulfatase (IDS) enzyme throughout the body and brain.
Denali is also evaluating DNL126 for the treatment of Sanfilippo syndrome type A (MPS IIIA). In September, Denali completed enrollment in the ongoing phase I/II study of DNL126 to support an accelerated approval path in Sanfilippo syndrome type A.
Denali had earlier announced data on DNL126 that demonstrated a significant reduction in cerebrospinal fluid (CSF) heparan sulfate (HS) from baseline, including normalization, and a safety profile that supports continued development. A global phase III confirmatory study is being planned.
Denali is also developing other candidates in partnership with Takeda (TAK - Free Report) and Biogen (BIIB - Free Report) .
Denali and partner Takeda have collaborated to develop DNL593, an investigational therapeutic designed to deliver progranulin across the blood-brain barrier for the treatment of granulin (GRN) mutation-associated frontotemporal dementia (FTD-GRN). A phase I/II study is ongoing.
Last month, DNLI submitted a clinical trial application for DNL628 (OTV:MAPT) to initiate clinical studies in Alzheimer’s disease, marking a significant milestone in advancing the oligonucleotide TransportVehicle (OTV) platform.
Denali and Biogen continue co-development of BIIB122.
Biogen is leading the global phase IIb LUMA study, evaluating BIIB122's impact on disease progression in early-stage PD. In May 2025, Biogen announced that the LUMA study was fully enrolled with a readout expected in 2026.
Meanwhile, Denali is conducting the phase IIa BEACON study, specifically enrolling participants with LRRK2-associated PD to assess how LRRK2 inhibition may impact this disease.
In October, Denali submitted an investigational new drug application for DNL952 (ETV:GAA) to begin clinical studies in Pompe disease.
Denali Therapeutics Inc. Price, Consensus and EPS Surprise
Denali Therapeutics Inc. price-consensus-eps-surprise-chart | Denali Therapeutics Inc. Quote
Our Take on DNLI’s Performance
While DNLI continues to advance its pipeline, a delay in approval of tividenofusp alfa is disappointing, as it is the company’s lead pipeline candidate.
Nonetheless, the company’s progress with DNL126 is encouraging as well.
The company’s sound cash position is a positive and ensures its ability to fund ongoing programs.
Zacks Rank and Key Pick
Denali currently carries a Zacks Rank #4 (Sell).
A better-ranked biotech stock is Alkermes (ALKS - Free Report) , which currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Alkermes’ earnings per share (EPS) estimates for 2025 have increased to $1.96 from $1.82, while those for 2026 have risen from $1.70 to $1.77 in the past 30 days. The stock has gained nearly 10.2% year to date.
Alkermes’ earnings beat estimates in three of the trailing four quarters and missed the mark in one, delivering an average surprise of 4.58%.